{
    "nctId": "NCT03059069",
    "officialTitle": "The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients",
    "inclusionCriteria": "* Type 2 diabetic patients\n* Age \u2265 50\n* Glycemic control: HbA1c \u2264 10.0%\n* 10 \u2264 Beck Depression Inventory (BDI) \\<30 points\n* Participants who can undergo contraception in case of being in childbearing period\n* Understands the study procedure, alternatives, and risks and voluntarily agrees to participate by giving written informed concent\n* Must have minimum age of 50 Years",
    "exclusionCriteria": "* Type 1 diabetes, Secondary diabetes, gestational diabetes\n* Ongoing dementia treatment or anti-depressive disorder medication\n* Uncontrolled psychiatric disorder\n* BDI \u2265 30 points\n* Heavy alcoholics\n* Underlying chronic liver disease (hemochromatosis, liver cell carcinoma, autoimmune liver disease, liver cirrhosis, chronic viral hepatitis)\n* Allergy or hypersensitivity to target medication or any of its components\n* Renal failure, moderate or severe renal impairment (estimated glomerular filtration rate \\< 30 mL/min/1.73 m2), or ongoing dialysis\n* Abnormal liver function (AST/ALT \\> x3 upper normal limit)\n* History of alcohol or drug abuse in the previous 3 months\n* Premenopausal women who are nursing or pregnant\n* Human immunodeficiency virus (HIV) or human immunodeficiency virus (AIDS)\n* chronic pancreatitis or pancreatic cancer"
}